China’s State FDA To Commence Drug Re-registration
This article was originally published in PharmAsia News
China's State FDA will begin re-registering drugs according to drug approval number to set up a comprehensive, authentic and reliable database. At the same time, the watchdog body aims to speed up the assessment of some backlogged 220,000 drugs that require reregistration under the newly implemented Drug Registration Regulation. The exercise seeks to use a regulated, structured administrative and technical methodology to weed out products that do not conform with required standards of production, safety and composition. Currently, many companies in China hold over 100 permits each but only produce about 20 drugs. (Click here for more - Chinese Language)
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.